Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02962492 · ClinicalTrials.gov registry record · NA
An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes
A NA study, sponsored by University at Buffalo.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
NCT02962492 is a NA study that has completed, run by University at Buffalo. The registered enrollment target is 70 participants.
The verdict
NCT02962492, a NA study, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
Study Summary
The study investigations include evaluation of the acute effects of a single dose of dapagliflozin (10mg), exenatide (5µg), a combination of exenatide and dapagliflozin or placebo under insulinopenic condition and the long term effect under basal conditions before and after 12 weeks treatment with dapagliflozin, Exenatide extended release, a combination of Exenatide extended release and dapagliflozin or placebo on ketogenesis, glucagon and lipolysis.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
- DRUG Exenatide/Exenatide extended release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-11-01 |
| Est. Completion | 2021-10-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02962492
The ClinicalTrials.gov registry entry for NCT02962492 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02962492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02962492 about?
NCT02962492 is a clinical study titled "An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes". The study investigations include evaluation of the acute effects of a single dose of dapagliflozin (10mg), exenatide (5µg), a combination of exenatide and dapagliflozin or placebo under insulinopenic condition and the long term effect under basal conditions before and after 12 weeks treatment with d...
What is the current status of trial NCT02962492?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2016-11-01. Estimated completion is 2021-10-24.
What interventions are being tested in trial NCT02962492?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG), Exenatide/Exenatide extended release (DRUG).
Who is sponsoring clinical trial NCT02962492?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.